Ground Swell Capital’s Traws Pharma TRAW Stock Holding History

Ground Swell Capital’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-562	Closed	-$6.28K	–	285
2024 Q2	$6.28K	Buy	+562	New	+$9.06K	﹤0.01%	159

Other funds holding TRAW

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

VWWMG

Vermillion & White Wealth Management Group Phoenixville, Pennsylvania $174M AUM 15.31% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Ground Swell Capital's TRAW Position: Q3 2024 in Review

Ground Swell Capital sold out of Traws Pharma (TRAW) in Q3 2024, closing a stake of 562 shares — an estimated $6.28K sold.

Ground Swell Capital first reported a position in TRAW in Q2 2024 and held it in 1 quarter. The position peaked at $6.28K in Q2 2024. 12 funds tracked by Wall St. Rank hold TRAW as of Q3 2024.

Ground Swell Capital reported no remaining Traws Pharma position as of Q3 2024 after selling out during the quarter.
Ground Swell Capital sold 562 Traws Pharma shares in Q3 2024, an estimated $6.28K.
Ground Swell Capital first reported a position in Traws Pharma in Q2 2024 and held it in 1 quarter.
Ground Swell Capital's Traws Pharma position peaked at $6.28K in Q2 2024.
12 funds tracked by Wall St. Rank held Traws Pharma as of Q3 2024.

Based on Ground Swell Capital's 13F filing for Q3 2024, filed 29 Oct 2024.